|
Our Spring Meeting is designed for the individuals responsible for discovering, developing, and producing biologicals worldwide. Presentations by the leading companies and academic development labs will share the most effective techniques and best practices needed to maximize product yields and facility utilization, while minimizing contamination risks and fulfilling regulatory expectations. Our goal is to expand the use of robust and reproducible process operations that can result in safer and more consistent products.
All three days are devoted to some of the industry’s most challenging applications. Here you’ll learn the latest technologies and best practices being used to develop and produce vaccines, viral gene vectors, cellular therapies, virus-like particles, and three-dimensional tissues.
Held March 10-12, 2014 in Washington, DC, three concurrent programs will be used to provide optimal coverage of this content, and you are welcome to attend any talks you choose from all three programs.
|
|
Please join us for our 2nd meeting on cell line development and banking, contaminant control, and rapid scale-up and testing methods for antibodies, recombinant proteins, vaccines, and conjugates. This highly innovative meeting is meant to share the techniques and best practices needed to establish stable and well-characterized cell banks, as well as the processes and testing methods for rapid scale-up of clinical trial materials and licensed products. Three concurrent programs will be used to provide optimal coverage of this content, and you are welcome to attend any talks you choose from all three programs.
ISBioTech meetings are designed for the professionals responsible for developing and producing biologics worldwide. You’ll learn and share with the industry’s leading companies as you hear from the individuals actually doing the work in the labs and production suites. We’ll cover the latest technologies and best practices needed for safe, effective, and consistent products.
Held October 27-29, 2014 in Rosslyn, Virginia, this meeting is meant to complement our Spring process development meeting on baculovirus expression technology, viral vectors and vaccines, and cellular therapies.
|
|
